Identification of a novel, pathogenic CREBBP variant in a patient with Menke-Hennekam syndrome: a Case Report

Anna Μaria Anastasiou1,2, Constantia Aristidou3, Athina Theodosiou4

  • 1Department of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Frontiers in Genetics
|August 27, 2025
PubMed

Insights

Menke-Hennekam syndrome (MKHK) is a rare genetic disorder. A novel CREBBP gene variant was identified in a patient, expanding understanding of MKHK subtypes and genotype-phenotype correlations.

Area of Science:

  • Genetics
  • Molecular Biology
  • Human Disease

Background:

  • Menke-Hennekam syndrome (MKHK) is a rare autosomal dominant disorder linked to loss-of-function variants in CREBBP or EP300 genes.
  • These genes encode transcriptional coactivators crucial for chromatin remodeling and gene expression regulation.

Observation:

  • A novel missense variant (NM_004380.3:c.5368T>C p.(Cys1790Arg)) in the CREBBP gene was identified in a 4-year-old male patient.
  • The patient presented with global developmental delay, intellectual disability, growth retardation, craniofacial dysmorphisms, excessive palmar skin, and lacked recurrent infections and autism spectrum behaviors.

Findings:

  • Trio-based exome sequencing confirmed the de novo origin of the CREBBP variant.
  • The variant was classified as pathogenic according to ACGS guidelines 2020.
  • Structural modeling suggested the p.(Cys1790Arg) substitution may disrupt the CBP TAZ2 domain's tertiary structure, potentially affecting transcription factor binding.

Implications:

  • This case expands the known clinical spectrum and genotype-phenotype relationships in Menke-Hennekam syndrome.
  • The findings contribute to the evolving classification of MKHK subtypes and highlight the role of CREBBP in neurodevelopmental disorders.